Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Income from Continuing Operations (2016 - 2025)

Guided Therapeutics' Income from Continuing Operations history spans 16 years, with the latest figure at 1218000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 86.81% to 1218000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 3198000.0, a 32.31% decrease, with the full-year FY2025 number at 3196000.0, down 32.23% from a year prior.
  • Income from Continuing Operations hit 1218000.0 in Q4 2025 for Guided Therapeutics, down from 742000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for GTHP hit a ceiling of 68000.0 in Q3 2021 and a floor of 1807000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 768650.0 across 5 years, with a median of 693000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 84.68% in 2021 and later tumbled 1720.59% in 2022.
  • Tracing GTHP's Income from Continuing Operations over 5 years: stood at 444000.0 in 2021, then crashed by 306.98% to 1807000.0 in 2022, then soared by 78.64% to 386000.0 in 2023, then plummeted by 68.91% to 652000.0 in 2024, then crashed by 86.81% to 1218000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for GTHP at 1218000.0 in Q4 2025, 742000.0 in Q3 2025, and 811000.0 in Q2 2025.